Mixed Phase 3 Results for AriBio’s Oral Alzheimer’s Drug: 31% Slower Decline in Monotherapy Population, No Significant Benefit Overall
AR1001 met the prespecified efficacy threshold in 604 patients not taking certain existing therapies but did not demonstrate a benefit across all 1,535 participants. The results offer clues for oral treatment while putting the eligible patient population and strength of evidence at the center of the next regulatory discussions.